The impact of the meningococcal serogroup C conjugate vaccine in Canada between 2002 and 2012

Clinical Infectious Diseases

Volumn 59, Issue 9, 2014, Pages 1208-1215

  Sadarangani, Manish ^a,b   Scheifele, David W ^a   Halperin, Scott A ^c   Vaudry, Wendy ^d   Saux, Nicole Le ^e   Tsang, Raymond ^f   Bettinger, Julie A ^a  

^a Department of Pediatrics   (Canada)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c IWK HEALTH CENTRE   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^f PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

conjugate vaccines; herd immunity; meningitis; meningococcal disease; serogroup C

Indexed keywords

MENINGOCOCCAL SEROGROUP C CONJUGATE VACCINE; MENINGOCOCCUS VACCINE; UNCLASSIFIED DRUG; SEROGROUP C MENINGOCOCCAL CONJUGATE VACCINE;

ADOLESCENT; ADULT; ARTICLE; HUMAN; INVASIVE MENINGOCOCCAL DISEASE; MAJOR CLINICAL STUDY; MENINGOCOCCOSIS; MORBIDITY; NEISSERIA MENINGITIDIS; POPULATION; PROSPECTIVE STUDY; CANADA; IMMUNOLOGY; INCIDENCE; MENINGOCOCCAL INFECTIONS; MICROBIOLOGY; MORTALITY;

ADULT; CANADA; HUMANS; INCIDENCE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP C; PROSPECTIVE STUDIES;

EID: 84913596979     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu597     Document Type: Article

References (31)

1. World Health Organization. Control of epidemic meningococcal disease: WHO practical guidelines. 2nd ed. Geneva, Switzerland: World Health Organization, 1998.
2. Cartwright KA, Stuart JM, Jones DM, Noah ND. The Stonehouse survey: Nasopharyngeal carriage of meningococci and Neisseria lactamica. Epidemiol Infect 1987; 99:591-601.
3. Caugant DA, Hoiby EA, Magnus P, et al. Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population. J Clin Microbiol 1994; 32:323-30.
4. An update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee Statement (ACS). Can Commun Dis Rep 2009; 35(ACS-3): 1-40.
5. Squires SG, Deeks SL, Tsang RS. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 1999, through 31 December, 2001. Can Commun Dis Rep 2004; 30:17-28.
6. An Advisory Committee Statement (ACS). Statement on recommended use of meningococcal vaccines. Can Commun Dis Rep 2001; 27:2-36.
7. Meningococcal vaccine for children. Paediatr Child Health 2002; 7: 425-9.
8. Statistics Canada. 2006 Census of Population. Available at: http://www12.statcan.gc.ca/census-recensement/2006/index-eng.cfm. Accessed 29 November 2013.
9. Gilca R, Deceuninck G, Lefebvre B, et al. The changing epidemiology of meningococcal disease in Quebec, Canada, 1991-2011: Potential implications of emergence of new strains. PLoS One 2012; 7:e50659.
10. Public Health Agency of Canada. National Enhanced Invasive Meningococcal Disease Surveillance System. Available at: http://www.phacaspc. gc.ca/im/vpd-mev/meningococcal-eng.php. Accessed 21 January 2013.
11. Ramsay M, Fox A. EU-IBIS Network. Invasive Neisseria meningitidis in Europe 2006. London: Health Protection Agency, 2007.
12. Campbell H, Andrews N, Borrow R, Trotter C, Miller E. Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: Effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity. Clin Vaccine Immunol 2010; 17:840-7.
13. Kaaijk P, van der Ende A, Berbers G, van den Dobbelsteen GP, Rots NY. Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? Experience from the Netherlands. BMC Infect Dis 2012; 12:35.
14. Safadi MA, McIntosh ED. Epidemiology and prevention of meningococcal disease: A critical appraisal of vaccine policies. Expert Rev Vaccines 2011; 10:1717-30.
15. Pollard AJ, Perrett KP, Beverley PC. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 2009; 9:213-20.
16. Auckland C, Gray S, Borrow R, et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. J Infect Dis 2006; 194:1745-52.
17. Public Health England. Meningococcal Reference Unit Laboratory confirmed reports. Available at: http://www.hpa.org.uk/webc/HPAwebFile/HPAweb-C/1317136087786. Accessed 5 December 2013.
18. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364:365-7.
19. Khatami A, Peters A, Robinson H, et al. Maintenance of immune response throughout childhood following serogroup C meningococcal conjugate vaccination in early childhood. Clin Vaccine Immunol 2011; 18:2038-42.
20. Perrett KP, Winter AP, Kibwana E, et al. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: A phase 4 clinical trial. Clin Infect Dis 2010; 50:1601-10.
21. Sakou II, Tzanakaki G, Tsolia MN, et al. Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine. Vaccine 2009; 27:4408-11.
22. Snape MD, Kelly DF, Lewis S, et al. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: Observational study. BMJ 2008; 336:1487-91.
23. European Centre for Disease Prevention and Control. Annual epidemiological report 2012: Reporting on 2010 surveillance data and 2011 epidemic intelligence data. Stockholm: ECDC, 2013.
24. Pollard AJ, Green C, Sadarangani M, Snape MD. Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease. Arch Dis Child 2013; 98:248-51.
25. De Wals P, De Serres G, Niyonsenga T. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec. JAMA 2001; 285:177-81.
26. British Columbia Centre for Disease Control. Immunization Uptake in Grade 6 Students. Vancouver, BC, Canada, 2013.
27. British Columbia Centre for Disease Control. Immunization Coverage: Kindergarten. Vancouver, BC, Canada, 2012.
28. Sundquist S, Dunlop T, Wright J, Findlater R, Grauer K. Immunization Report 2010: Saskatoon Health Region 2011.
29. Public Health Ontario. Monthly Infectious Diseases Surveillance Report 2013.
30. Update on the use of quadrivalent conjugate meningococcal vaccines. Can Commun Dis Rep 2013; 39(ACS-1): 1-40.
31. Snape MD, Pollard AJ. The beginning of the end for serogroup B meningococcus? Lancet 2013; 381:785-7.